93. 原発性胆汁性胆管炎 Primary biliary cholangitis Clinical trials / Disease details
臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115
Showing 1 to 10 of 140 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05751967 (ClinicalTrials.gov) | February 22, 2023 | 13/12/2022 | Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis | A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis and an Inadequate Response to Ursodeoxycholic Acid A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: Fenofibrate Combine ... | Primary Biliary Cholangitis | Drug: Placebo Combined With Ursodeoxycholic Acid;Drug: Fenofibrate Combined With Ursodeoxycholic Acid Drug: Placebo Combined With Ursodeoxycholic Acid;Drug: FenofibrateCombined With Ursodeoxycholic Acid ... | Xijing Hospital of Digestive Diseases | NULL | Recruiting | 18 Years | 75 Years | All | 150 | Phase 3 | China |
| 2 | NCT05749822 (ClinicalTrials.gov) | February 17, 2023 | 29/12/2022 | Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis | Fenofibrate Combined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliary Cholangitis Who Had an Inadequate Response to Ursodeoxycholic Acid Fenofibrate Combined With Ursodeoxycholic Acidin Compensated Cirrhosis Patients With Primary Biliary ... | Primary Biliary Cholangitis | Drug: Fenofibrate 200mg;Drug: Placebo;Drug: UDCA | Xijing Hospital of Digestive Diseases | NULL | Recruiting | 18 Years | 75 Years | All | 104 | Phase 2/Phase 3 | China |
| 3 | EUCTR2021-001431-56-FI (EUCTR) | 04/05/2022 | 10/03/2022 | Clinical study comparing two doses of norucholic acid against placebo in the treatment of a liver disease called primary biliary cholangitis in patients without sufficient response to ursodeoxycholic acid Clinical study comparing two doses of norucholic acid against placebo in the treatment of a liver di ... | Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients with an inadequate response to ursodeoxycholic acid - NCA vs. placebo in PBC Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses ... | primary biliary cholangitis MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] primary biliary cholangitis MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primar ... | Product Name: Norucholic acid (NCA) 500 mg Product Code: NCA 500mg INN or Proposed INN: Norucholic acid Other descriptive name: norucholic acid Product Name: Norucholic acid(NCA) 500 mg Product Code: NCA 500mg INN or Proposed INN: Norucholic acid ... | Dr. Falk Pharma GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Phase 2 | France;Finland;Poland;Belgium;Denmark;Austria;Norway;Netherlands;Germany;United Kingdom;Switzerland | ||
| 4 | NCT05293938 (ClinicalTrials.gov) | March 28, 2022 | 4/3/2022 | A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients | Study Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis Study Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients Wi ... | Primary Biliary Cholangitis | Drug: Obeticholic Acid 5 MG;Drug: Obeticholic Acid 10 MG;Drug: Standard of Care: UDCA | Intercept Pharmaceuticals | Global PBC Study Group;Target RWE;Syneos Health;UK PBC Study Group | Enrolling by invitation | 18 Years | N/A | All | 2350 | United States | |
| 5 | EUCTR2021-001431-56-DE (EUCTR) | 07/03/2022 | 03/11/2021 | Clinical study comparing two doses of norucholic acid against placebo in the treatment of a liver disease called primary biliary cholangitis in patients without sufficient response to ursodeoxycholic acid Clinical study comparing two doses of norucholic acid against placebo in the treatment of a liver di ... | Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients with an inadequate response to ursodeoxycholic acid - NCA vs. placebo in PBC Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses ... | primary biliary cholangitis MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] primary biliary cholangitis MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primar ... | Product Name: Norucholic acid (NCA) 500 mg Product Code: NCA 500mg INN or Proposed INN: Norucholic acid Other descriptive name: norucholic acid Product Name: Norucholic acid(NCA) 500 mg Product Code: NCA 500mg INN or Proposed INN: Norucholic acid ... | Dr. Falk Pharma GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Phase 2 | Finland;Spain;Lithuania;Austria;Switzerland;United Kingdom;France;Belgium;Poland;Denmark;Germany;Netherlands;Norway Finland;Spain;Lithuania;Austria;Switzerland;United Kingdom;France;Belgium;Poland;Denmark;Germany;Net ... | ||
| 6 | EUCTR2020-004348-27-DK (EUCTR) | 04/03/2022 | 22/11/2021 | A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA). A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cho ... | RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) - RESPONSE RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Sel ... | Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and potentially life threatening autoimmunedisease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA). MedDRA version: 21.0;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Body processes [G] - Immune system processes [G12] Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and poten ... | Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpa ... | CymaBay Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | Mexico;Canada;Argentina;Poland;Belgium;Romania;Germany;New Zealand;United States;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Switzerland;Italy;France;Australia;Denmark;Netherlands;Korea, Republic of;Czechia;Turkey;Austria;United Kingdom;Hungary Mexico;Canada;Argentina;Poland;Belgium;Romania;Germany;New Zealand;United States;Greece;Spain;Ukrain ... | ||
| 7 | NCT05104853 (ClinicalTrials.gov) | January 25, 2022 | 22/10/2021 | Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Bi ... | A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodyna ... | Primary Biliary Cholangitis | Drug: CNP-104;Drug: Placebo | COUR Pharmaceutical Development Company, Inc. | NULL | Recruiting | 18 Years | 75 Years | All | 40 | Phase 1/Phase 2 | United States |
| 8 | NCT04956328 (ClinicalTrials.gov) | July 22, 2021 | 1/7/2021 | Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC) Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid(UDCA) in Patients With Primay B ... | A Multi-center, Randomized, Double-blind Trail Evaluating the Efficacy and Safety of Combination of Obecholic Acid and UDCA Compared With UDCA Monotherapy in PBC Patients With an Inadequate Response to UDCA . A Multi-center, Randomized, Double-blind Trail Evaluating the Efficacy and Safety of Combination of ... | Primary Biliary Cirrhosis | Drug: Obeticholic Acid Tablets;Drug: UDCA;Drug: Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NULL | Recruiting | 18 Years | 75 Years | All | 120 | Phase 3 | China |
| 9 | EUCTR2020-004348-27-RO (EUCTR) | 08/07/2021 | 19/04/2022 | A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA). A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cho ... | RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) - RESPONSE RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Sel ... | Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and potentially life threatening autoimmunedisease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA).;Therapeutic area: Body processes [G] - Immune system processes [G12] Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and poten ... | Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpa ... | CymaBay Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | United States;Greece;Spain;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Romania;Denmark;Australia;Netherlands;Germany;New Zealand;Korea, Republic of United States;Greece;Spain;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexic ... | ||
| 10 | EUCTR2020-004348-27-DE (EUCTR) | 07/07/2021 | 07/01/2021 | A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA). A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cho ... | RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) - RESPONSE RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Sel ... | Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and potentially life threatening autoimmunedisease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA).;Therapeutic area: Body processes [G] - Immune system processes [G12] Primary biliary cholangitis (PBC, formerly known as primary biliarycirrhosis) is a serious and poten ... | Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpar Product Code: MBX-8025 INN or Proposed INN: SELADELPAR Product Name: Seladelpa ... | CymaBay Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 3 | United States;Greece;Spain;Ukraine;Russian Federation;Israel;Chile;Italy;France;Australia;Denmark;Netherlands;Korea, Republic of;Czechia;Turkey;United Kingdom;Hungary;Mexico;Canada;Argentina;Belgium;Poland;Romania;Germany;New Zealand United States;Greece;Spain;Ukraine;Russian Federation;Israel;Chile;Italy;France;Australia;Denmark;Ne ... |